Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
Retrieved on:
Monday, November 6, 2023
NAMD, Neovascularization, HKEX, CFP, Trial of the century, CST, Incidence, Eye, Ophthalmology, Infrared spectroscopy correlation table, Treatment, DME, AAO, Injection, Fibrosis, MAD, SAD, Inflammation, Drug development, SAE, Retinal vasculitis, Anetoderma, Diabetic retinopathy, American Academy, American Academy of Ophthalmology, Annual general meeting, Paratriathlon, Safety, Visual acuity, Moran Eye Center, Patient, Hospital, Anti-VEGF, Pharmaceutical industry, Phosphorus, Food and Drug Administration Safety and Innovation Act
The primary endpoint was the change from baseline in best-corrected visual acuity (BCVA) in the study eye at 36 weeks.
Key Points:
- The primary endpoint was the change from baseline in best-corrected visual acuity (BCVA) in the study eye at 36 weeks.
- In terms of safety, the incidence of adverse events were similar in the IBI302 2 mg group, IBI302 4 mg group, and the aflibercept 2 mg group.
- This is a Phase 1 clinical study evaluating the safety, tolerability, and efficacy of IBI324 in the treatment of DME (ClinicalTrials.gov: NCT05489718).
- We look forward to advancing the clinical development progress and hope Innovent's innovative medicines can benefit more patients."